triple glp-1/gip/glucagon receptor agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 Effects of triple GLP-1/GIP/Glucagon agonists.
Description
Conclusion Tirzepatides approval as the first drug for OSA expands treatment options for patients with both obesity and sleep apnea
High acceptance of new drug therapies, presence of major drug manufacturers and rising awareness among physicians regarding the benefits of incretin-based therapies have been the key growth factors
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
